The Indian Patent Office has rejected a patent application for the BPaL regimen, a groundbreaking treatment for ...

Despite a 30% cap on trade margins for non-scheduled cancer drugs, prices for branded cancer medications remain unchanged, ...

Despite a $2.2 billion setback due to failed drug trials, Novartis raises its profit forecast for the year, highlighting ...

The FDA has cautioned Amgen about a promotional video for Vectibix, its colorectal cancer drug, which allegedly ...

Eli Lilly reveals significant leadership transitions as Patrik Jonsson announces retirement and Ilya Yuffa steps into the ...

Artiva Biotherapeutics has decided to suspend the development of its experimental cell therapy AlloNK, following two patient ...

The CDSCO has raised a public alert regarding a counterfeit batch of the liver medication Defitelio, prompting patients to ...

India's drug regulator DCGI cancels the import registration of FatX, a cosmetic product marketed with unauthorized ...

Cipla targets a first wave launch of its Keytruda biosimilar QL2107 in the US after patent expiry in 2029, with expectations ...

Cipla's bispecific ADC rolditamig deruxtecan demonstrates a remarkable 71% reduction in disease progression for late-stage ...

Mankind Pharma's net profit rises to ₹716 crore for Q2 FY27, driven by strong sales growth while seeking transformation in ...

In its Q2 FY27 report, Torrent Pharma experiences a 9.6% decline in net profit to ₹534 crore while showcasing a robust 50.8% ...